Merck & Co. (NYSE: MRK)

This lawsuit is for anyone who acquired securities in Merck & Co. (NYSE: MRK) securities from February 3, 2022 through February 3, 2025

The lawsuit alleges that the Company and certain of its executives violated federal law. Specifically, the lawsuit alleges that, throughout the time period mentioned above, the Company misled investors regarding its financial condition. More specifically, the lawsuit alleges that the Company misled investors by stuffing its Chinese channels of distribution with its HPV vaccine, Gardasil, for the purpose of overstating revenue.

On July 30, 2024, Merck released its second quarter 2024 financial report and disclosed a significant reduction in Gardasil vaccinations, resulting in an overabundance of inventory at Merck’s Chinese distributer. The Company announced that its shipments of Gardasil to China may fall below contracted levels for 2024. On this news, the price of the Company’s stock dropped precipitously on unusually heavy trading volume. Then, on February 4, 2025, Merck disclosed that it would entirely cease shipments of Gardasil to China “through at least midyear” to facilitate a “rapid reduction of inventory,” citing a continued over-inflation of channel inventories as demand in China had “not recovered to the level [the Company] had expected.” Merch also announced that it would no longer achieve its long-forecasted $11 billion in sales of Gardasil by 2030. On this news, the price of the Company’s stock again dropped precipitously on unusually heavy trading volume.

The Law Offices of Howard G. Smith seeks to recover damages on behalf of class members. If you acquired securities in Merck & Co. (NYSE: MRK) securities from February 3, 2022 through February 3, 2025 you may join the lawsuit by submitting your information online, or you may call the Law Offices of Howard G. Smith and speak to Mr. Smith directly to learn how he can protect your rights.